Clinical trials confirm that SGLT2 inhibitors reduce the risk of composite renal endpoints by 30% (including end-stage renal disease and serum creatinine doubling), accompanied by modest reductions in HbA1c (0.25%) and body weight (0.8 kg) (20). Here, SLC5A2 is linked to chronic kidney disease.